GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Net Policyholder Benefits/Claims

PCI Biotech Holding ASA (FRA:4QG) Net Policyholder Benefits/Claims


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


PCI Biotech Holding ASA (FRA:4QG) Business Description

Industry
Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.